Archive for the ‘Commercialization’ Category

Right Turn: Stem cell “gun” for wound healing

Author: Stacey Johnson, 06/02/17

It has been said that the pen is mightier than the sword. Where, then, does the gun factor in? I was amazed, last year, when I learned of the “biopen,” a medical device that draws stem cells to repair damaged or worn cartilage and then the cartilage heals itself with its own cells. From what…Read more

Five regenerative medicine workshops to attend this summer

Author: Guest, 05/15/17

Amin Adibi is a biomedical engineer and a health data analyst at the University of British Columbia. His areas of interest include cell manufacturing and bioprocess optimization, clinical translation of cellular therapies, health outcomes and cost-effectiveness modelling. Amin has an MSc degree from University of Calgary, where he focused on developing adjuvant MSC-based therapies for…Read more

Funding the future: Highlights from Bloom Burton & Co.’s Healthcare Investor Conference

Author: Guest, 05/04/17

Samantha Yammine is a PhD Candidate in Dr. Derek van der Kooy’s lab at the University of Toronto studying how stem cells develop and maintain the brain. Samantha is passionate about science advocacy, policy, and education, and is an avid science communicator. You can find her sharing science straight from the lab on Instagram (@science.sam),…Read more

Filling the void: A scientist’s introduction to commercialization/clinical translation

Author: Holly Wobma, 04/26/17

For anybody who has invested a great deal of time into a research project, you probably feel a certain sense of expertise on the topic. Sure, it is impossible to know a whole field (every answer raises more questions), and lab work is rife with puzzlement and failures, but at the end of the day,…Read more

Right Turn: Sightings of innovation in Canada

Author: Stacey Johnson, 04/14/17

If you are a knowledge worker, it may seem as though “innovation” is on everyone’s lips these days. First, Canadians saw Industry Canada renamed Innovation, Science and Economic Development when Prime Minister Trudeau unveiled his first cabinet. Then, Budget 2017, titled “building a strong middle class” could have had “the innovation budget” as its working…Read more

The long slog of medical R&D and finding inspiration

Author: Elizabeth Csaszar, 03/27/17

Research and development (R&D) of a medical therapeutic is a long slog. This isn’t news to anyone working in the field. The average time to bring a new drug product to market is over a decade. Moreover, this is the timeline when everything progresses well – funding and business decisions align, manufacturing processes come together,…Read more

Improving ultrasound imaging may have applications in regenerative medicine

Author: Guest, 03/13/17

Andy Bell, a writer working with Toronto3dprinting, loves to write about different topics related to technological gadgets and gears. 3D printing is his current interest. Though ultrasound technology is commonly associated with the imaging of fetuses in the womb, its applications are much more than just imaging. The acoustic waves generated by ultrasound devices can…Read more

Right Turn: New stem cell product for ALS seeking approval in Canada

Author: Stacey Johnson, 02/24/17

This week, BrainStorm Cell Therapeutics issued a news release announcing its intent to seek early regulatory approval to distribute its Amyotrophic Lateral Sclerosis (ALS) product to patients in Canada. This news was eagerly received by patient groups in Canada and internationally. ALS, also known as Lou Gehrig’s Disease, is a progressive neuromuscular disease in which…Read more

Learning About Industry from the Insiders at Phacilitate Cell and Gene Therapy World 2017

Author: Nicole Forgione, 02/08/17

In January, I attended Phacilitate’s Cell and Gene Therapy World in Miami, Florida. At this meeting industry leaders from around the world gather to discuss manufacturing, regulation and adoption of cell and gene therapies (C&GT). This was my first industry-focused conference, and it was a great chance to learn the ropes from experienced players in…Read more

Peter Zandstra and CCRM: Making cell therapies a commercial reality

Author: Guest, 01/31/17

Dr. Rohin Iyer is currently a Development Manager at GE Healthcare / CCRM. He did his PhD in Biomedical Engineering at the University of Toronto, and has been working in the field of stem cells and tissue engineering for over 12 years. He is an avid tweeter (follow @DrRohinIyer) on cell therapies and regenerative medicine. …Read more